Bristol-Myers Squibb (NYSE:BMY) Shares Down 0.1%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) shares traded down 0.1% during mid-day trading on Tuesday . The stock traded as low as $43.97 and last traded at $44.59. 3,674,759 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 15,820,087 shares. The stock had previously closed at $44.64.

Analysts Set New Price Targets

A number of research firms have commented on BMY. Redburn Atlantic cut shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and decreased their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Societe Generale cut shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a research report on Thursday, April 18th. StockNews.com lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. Finally, BMO Capital Markets dropped their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $60.00.

Bristol-Myers Squibb Stock Down 1.5 %

The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The company has a market cap of $89.11 billion, a PE ratio of -14.18, a P/E/G ratio of 15.47 and a beta of 0.39. The business's 50 day moving average is $50.81 and its 200-day moving average is $50.93.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts' consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company's revenue was up 4.7% on a year-over-year basis. During the same period last year, the business earned $2.05 EPS. As a group, analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. Bristol-Myers Squibb's payout ratio is currently -77.42%.

Institutional Trading of Bristol-Myers Squibb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Longbow Finance SA purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at $1,730,000. Norden Group LLC grew its holdings in shares of Bristol-Myers Squibb by 30.2% during the first quarter. Norden Group LLC now owns 13,846 shares of the biopharmaceutical company's stock worth $751,000 after purchasing an additional 3,213 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Bristol-Myers Squibb by 97.2% during the first quarter. Van ECK Associates Corp now owns 7,949,173 shares of the biopharmaceutical company's stock worth $431,084,000 after purchasing an additional 3,918,234 shares during the last quarter. HB Wealth Management LLC increased its position in shares of Bristol-Myers Squibb by 6.8% during the first quarter. HB Wealth Management LLC now owns 69,801 shares of the biopharmaceutical company's stock worth $3,785,000 after purchasing an additional 4,451 shares in the last quarter. Finally, Woodward Diversified Capital LLC lifted its holdings in shares of Bristol-Myers Squibb by 15.1% in the 1st quarter. Woodward Diversified Capital LLC now owns 4,931 shares of the biopharmaceutical company's stock valued at $267,000 after purchasing an additional 647 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.